Trial Profile
Clinical study of Apatinib combined with chemotherapy or single Drug for second-line treatment failure in advanced ovarian cancer
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 15 Mar 2018 New trial record